MedTrace Logo

Oxidized LDL With Oxygen Therapy in Acute Coronary Syndrome.

NCT03830138 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2019-02-05

No results posted yet for this study

Summary

Coronary artery disease (CAD) is increasing rapidly in Egyptian people and manifesting a younger age. Higher plasma low-density lipoprotein cholesterol (LDL-C), is a major predictor for the development of CAD. However, whether oxidized-LDL (ox-LDL) can be used as a risk factor for myocardial infarction (MI) has not been fully investigated. Therefore, the aim of the present study was to examine the role of ox-LDL as a risk factor for the presence and clinical outcomes in patients with MI.

Conditions

  • Acute Coronary Syndrome

Interventions

GENETIC

Oxidized-LDL gene polymorphism

Oxidized-LDL gene polymorphism will be measured by RFLP. In addition, Oxidized-LDL will be measured in the plasma by ELISA

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-02-20
Primary Completion
2019-04-01
Completion
2019-05-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03830138 on ClinicalTrials.gov